GGrantIndex
← Leaderboards

Dirk Homann

University Of Colorado Denver

$7,889,596
Attributed
$18,621,376
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.2M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$18,621,376 · 9

By mechanism

R01$10,740,508 · 5
U01$6,605,737 · 1
R21$1,275,131 · 3

Most similar at University Of Colorado Denver

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsImmuneInsulin-Dependent Diabetes MellitusDiabetes MellitusPreventIsletBeta CellTissuesInsulinInsightPreventionPhenotypeImmune ResponseNon-DiabeticGenerationsResolutionMolecularPancreasDesignPathogenesisFoundationsIslets Of LangerhansPrediabetes SyndromeModality

Grant awards (32)

The KQ1 serum study: soluble biomarkers for T1D risk, development & progression$1,095,529
R01 · FY2025 · DK · contact PI
The KQ1 serum study: soluble biomarkers for T1D risk, development & progression$1,230,771
R01 · FY2024 · DK · contact PI
Human Pancreas Analysis Program-T2D$1,055,999
U01 · FY2024 · DK
Human Pancreas Analysis Program-T2D$1,100,000
U01 · FY2023 · DK
Experimental and natural SARS-CoV-2 infection of the human pancreas$418,396
R01 · FY2023 · DK · contact PI
Human Pancreas Analysis Program-T2D$350,000
U01 · FY2023 · DK
Human Pancreas Analysis Program-T2D$1,100,000
U01 · FY2022 · DK
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2022 · AI
Experimental and natural SARS-CoV-2 infection of the human pancreas$418,419
R01 · FY2022 · DK · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2021 · AI
Experimental and natural SARS-CoV-2 infection of the human pancreas$453,320
R01 · FY2021 · DK · contact PI
Human Pancreas Analysis Program-T2D$1,100,000
U01 · FY2020 · DK
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2020 · AI
Dextran Sulfate, Beta Cell Preservation and Immune Regulation in Type 1 Diabetes$409,742
R01 · FY2020 · DK
Human Pancreas Analysis Program-T2D$1,899,738
U01 · FY2019 · DK
Integrated Functional Histopathology of the Diabetic Human Pancreas$699,000
R01 · FY2019 · AI
Dextran Sulfate, Beta Cell Preservation and Immune Regulation in Type 1 Diabetes$409,742
R01 · FY2019 · DK
Mapping Essential Elements and Toxic Metals in the Human Pancreas in Health and Disease$211,875
R21 · FY2019 · ES · contact PI
Integrated Functional Histopathology of the Diabetic Human Pancreas$719,000
R01 · FY2018 · AI
Dextran Sulfate, Beta Cell Preservation and Immune Regulation in Type 1 Diabetes$413,108
R01 · FY2018 · DK
Mapping Essential Elements and Toxic Metals in the Human Pancreas in Health and Disease$254,250
R21 · FY2018 · ES · contact PI
Dextran Sulfate, Beta Cell Preservation and Immune Regulation in Type 1 Diabetes$423,750
R01 · FY2017 · DK
Decay accelerating factor dependent inhibition of T cell immunity$211,875
R21 · FY2017 · AI
Regulation of Pathogen-specific T Cell Immunity by Adenosine Generation$423,750
R01 · FY2016 · AI · contact PI
Decay accelerating factor dependent inhibition of T cell immunity$254,250
R21 · FY2016 · AI
Regulation of Pathogen-specific T Cell Immunity by Adenosine Generation$423,750
R01 · FY2015 · AI · contact PI
Regulation of Pathogen-specific T Cell Immunity by Adenosine Generation$300,156
R01 · FY2014 · AI · contact PI
Regulation of pathogen-specific T cell immunity by adenosine generation$112,657
R01 · FY2014 · AI · contact PI
Regulation of pathogen-specific T cell immunity by adenosine generation$336,904
R01 · FY2013 · AI · contact PI
Regulation of pathogen-specific T cell immunity by adenosine generation$355,514
R01 · FY2012 · AI · contact PI
Maturation of established antiviral CD8 T cell memory$150,381
R21 · FY2006 · AG · contact PI
Maturation of established antiviral CD8 T cell memory$192,500
R21 · FY2005 · AG